Zevra Therapeutics (ZVRA) Projected to Post Earnings on Thursday

Zevra Therapeutics (NASDAQ:ZVRA) is anticipated to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Zevra Therapeutics to post earnings of ($0.39) per share and revenue of $8.93 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $8.21 on Tuesday. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a market cap of $444.29 million, a PE ratio of -4.17 and a beta of 1.98. The firm’s fifty day simple moving average is $7.90 and its 200-day simple moving average is $8.19.

Analyst Ratings Changes

Several analysts have recently issued reports on ZVRA shares. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Canaccord Genuity Group raised their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, March 13th. Guggenheim upped their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, March 13th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Finally, JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Zevra Therapeutics presently has an average rating of “Buy” and an average price target of $22.29.

Insider Buying and Selling at Zevra Therapeutics

In related news, CFO R. Laduane Clifton sold 11,000 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the sale, the chief financial officer now owns 51,361 shares of the company’s stock, valued at $403,697.46. This represents a 17.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director John B. Bode bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The stock was bought at an average price of $7.96 per share, with a total value of $79,600.00. Following the transaction, the director now directly owns 40,000 shares in the company, valued at $318,400. This represents a 33.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 85,773 shares of company stock valued at $674,176 in the last ninety days. Company insiders own 2.40% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.